Heart FailureAISEARHFNCT07021599
Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure
A study testing Tailored AI echocardiogram analysis and reporting system in people with Heart Failure, run by Prince of Wales Hospital, Shatin, Hong Kong at 1 site in Hong Kong.
Trial summary
This is a non-inferiority, three-year, multicenter, double-blinded randomized controlled study of an AI versus experienced sonographer echocardiogram analysis in HF patients. Consecutive patients presented for echocardiogram examination with new or worsening HF symptom and positive HF blood markers will be recruited. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- Tailored AI echocardiogram analysis and reporting system
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 514 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Jul 2025to 3 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 years or above
- Has new or worsening of heart failure symptoms
- Elevated heart failure blood markers (N-terminal prohormone of brain natriuretic peptide, "NTproBNP") within 3 months from enrolment or by point-of-care blood test, to ensure that the patient's symptoms are cardiac origin
- Provision of written informed consent
Who cannot join
- Known severe valvular heart disease
- Prior prosthetic valve implantation
- Previously known or suspected >=severe tricuspid regurgitation, >=moderate aortic regurgitation, >=moderate mitral stenosis or pericardial disease during detected during image acquisition
- Insufficient image quality for proper analysis determined by the scanning sonographer (estimated to be 15% of all echocardiograms screened)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure: A Randomized Controlled Trial
This is a non-inferiority, three-year, multicenter, double-blinded randomized controlled study of an AI versus experienced sonographer echocardiogram analysis in HF patients. Consecutive patients presented for echocardiogram examination with new or worsening HF symptom and positive HF blood markers will be recruited. A target of 514 patients will be randomized 1:1 to receive either AI or sonographer echocardiogram analysis. The primary endpoint of diagnostic accuracy is the complete agreement of disease grading with an experienced cardiologist (American Society of Echocardiography level III) using a standardized grading chart. Important secondary endpoints include the time used for echocardiogram report drafting and report endorsement, 6-month heart failure symptom and hospitalization, and the cost-effectiveness of AI to increase echocardiogram service. Clinical, biochemical and echocardiographic predictors of worsening of heart failure and hospitalization will be identified.
Read the detailed description
Background Unmet Need for Streamlined Echocardiogram Algorithm Heart failure (HF) is a global pandemic affecting more than 64 million people in the world.
In Hong Kong, the prevalence of HF is estimated to be 2-3% with a steep rise of new onset HF hospitalization in the older age group. The estimated annual worldwide economic burden of HF was 108 billion United States dollars, with direct costs to healthcare systems accounted for 60% and indirect costs to society driven by premature mortality, morbidity and lost productivity accounted for the remaining 40%. Timely diagnosis of HF etiology with early appropriate treatment are critical to reduce HF hospitalization and mortality. While HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) requires different guideline directed medical therapy (GDMT), HF patients with severe valvular heart disease requires interventional treatment. Echocardiogram (cardiac ultrasound) is the key diagnosticmodality to phenotype HF and to guide subsequent appropriate treatment. Access to echocardiogram in Asia Pacific is severely limited (e.g. average waiting time in Hong Kong for routine echocardiogram is 12-18 months), which results in delay in appropriate treatment and hence poor outcomes. While image acquisition is easier to teach, analysis in echocardiogram is time consuming and requires years of training to become proficient, and yet has significant inter-observer variability. Therefore, there is a shortage of fully trained sonographers globally. A streamlined echocardiogram analysis pathway that can enhance the efficiency while improving the diagnostic accuracy of HF etiology is appealing.
Emerging role of Artificial Intelligence in Echocardiogram Artificial intelligence (AI) has emerged as a useful tool with the potential to enhance cardiovascular care including in disease diagnosis, treatment guidance and outcome prediction. Collaborator of this study, David Ouyang et al., has developed machine learning algorithm for fully automated assessment of left ventricular ejection function (LVEF), aortic valve stenosis (AS) and mitral valve regurgitation (MR), with similar accuracy compared to manual analysis by experienced sonographers with reference to cardiologists ("gold standard"). Similar works has also been done by other teams. However, most of these validation studies are conducted based on retrospective echocardiogram cohort. Besides, there can be bias when a different sonographer than the scanning sonographer interprets the images, and that potentially compromised the real-life diagnostic accuracy of sonographers.
Local Heart Failure Data and Application Artificial Intelligence in Echocardiogram Studies from our team has demonstrated that early diagnosis and intensified HF GDMT can reduce HF hospitalization from 13.1% to 8.6% (Hazard ratio = 0.65, p<0.01). Besides, a strong association of 30-day unplanned HF hospitalization with severe valvular heart disease, mostly AS or MR, was found (Odd ratio =72.04, p=0.03). This implies that early phenotyping the mechanism of HF is important. From our unpublished pilot data of patients presented with HF symptom, echocardiogram image acquisition took only 54.2% of the total echocardiogram process time while the remaining were used for analysis by sonographer. When compared, AI used a significantly shorter time for echocardiogram analysis (324 seconds vs 1057 seconds, p<0.01), with a 91.6% agreement rate on LVEF grading and severity of AS and MR. However, this pilot data was collected retrospectively, and the sample size was small. Therefore, it remains unclear whether AI is as accurate and more efficient than experienced sonographers in analyzing multiple possible echocardiogram abnormalities that can interact with each other for HF patients. Moreover, whether the addition of AI analysis will affect the final grading by cardiologists has not been studied.
In this research project proposal, Investigator aim to assess whether a tailored AI echocardiogram analysis and reporting system is as accurate as an experienced sonographer in HF patients by conducting a multicenter double-blinded randomized controlled study.
- Conditions
- Heart Failure
- Being tested
- Tailored AI echocardiogram analysis and reporting system
- Keywords
- Echocardiogram, Artificial Intelligence, Alogrithm, Echocardiological image analysis
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored AI echocardiogram analysis and reporting systemDiagnostic test
In the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized.
| Study group | Role | What they receive |
|---|---|---|
| Tailored AI echocardiogram analysis and reporting system | Experimental | An experienced cardiologist will be provided with AI's measurements, draft disease grading and report for review. The experienced cardiologist will provide a final grading of left ventricular function, AS and MR on the standardized grading chart, and endorse the final echocardiogram report. Receives: Diagnostic Test: Tailored AI echocardiogram analysis and reporting system |
| Echocardiologist interpretation and analysis of Echo images | Active comparator | An experienced cardiologist (with American Society of Echocardiography level III capacity), will be provided with sonographer's measurements, draft disease grading and report for review. Receives: Diagnostic Test: Tailored AI echocardiogram analysis and reporting system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of complete agreement in LVEF assessments
To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist
Measured: 6 month
Rate of complete agreement in assessments of AS severity
To assess the rate of agreement in severity of AS assessments between AI and sonographers with final adjudication by experienced cardiologist
Measured: 6 month
Rate of complete agreement in assessment of MR severity
To assess the rate of agreement in severity of MR assessments between AI and sonographers with final adjudication by experienced cardiologist
Measured: 6 month
Secondary outcomes (23)
Time used for image acquisition echocardiogram process
Compare the time used by AI system and sonographers for image acquisition.
Measured: 6 month
Time used forreport drafting echocardiogram process
Compare the time used by AI system and sonographers for report drafting.
Measured: 6 month
Time used for report endorsement
Compare the time used by AI system and sonographers for report endorsement.
Measured: 6 month
Time used for total echocardiogram process
Compare the time used by AI system and sonographers for total echocardiogram process.
Measured: 6 month
NYHA classification
Compare of NYHA classification of subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
Symptom burden
Compare of symptom burden of subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
NTproBNP level
Compare of NTproBNP level of subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
Rate of heart failure hospitalisation
Compare of Rate of heart failure hospitalisation of subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
Rate of all-cause mortality
Compare of Rate of all-cause mortality of subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
Dosage of GDMT
Compare GDMT dosage change of Heart Failure subjects at 6 month and baseline between 2 intervention groups
Measured: 6 month
Rate of valvular intervention
Compare Rate of valvular intervention in subjects with severe valvular heart disease at 6 month and baseline between 2 intervention groups
Measured: 6 month
Rate of LVEF assessment change made by cardiologist on AI generated reports
Rate of LVEF assessment change made by cardiologist on AI generated reports
Measured: 6 month
Rate of change in severity of AS made by cardiologist on AI generated reports
Rate of change in severity of AS made by cardiologist on AI generated reports
Measured: 6 month
Rate of change in severity of MR made by cardiologist on AI generated reports
Rate of change in severity of MR made by cardiologist on AI generated reports
Measured: 6 month
Subgroup analysis of LVEF agreement rate in low complexity disease
To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease
Measured: 6 month
Subgroup analysis of LVEF agreement rate in intermediate complexity disease
To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease
Measured: 6 month
Subgroup analysis of LVEF agreement rate in high complexity disease
To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease
Measured: 6 month
Subgroup analysis of severity of AS agreement rate in low complexity disease
To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease
Measured: 6 month
Subgroup analysis of severity of AS agreement rate in intermediate complexity disease
To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease
Measured: 6 month
Subgroup analysis of severity of AS agreement rate in high complexity disease
To assess the rate of agreement in severity of AS between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease
Measured: 6 month
Subgroup analysis of severity of MR agreement rate in low complexity disease
To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in low complexity disease
Measured: 6 month
Subgroup analysis of severity of MR agreement rate in intermediate complexity disease
To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in intermediate complexity disease
Measured: 6 month
Subgroup analysis of severity of MR agreement rate in high complexity disease
To assess the rate of agreement in severity of MR between AI and sonographers with final adjudication by experienced cardiologist in high complexity disease
Measured: 6 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2025
- Study start1 Jul 2025
- Primary completion3 Jul 2028 (estimated)
- Study completion3 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 514 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr So Chak Yu kent, Prince of Wales Hospital, Shatin, Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07021599
- Sponsor's protocol ID
- 2024.587
- Acronym
- AISEARHF
- Status last verified
- Sep 2026
- First submitted
- 5 Jun 2025
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Artificial Intelligence Versus Sonographer Echocardiogram Analysis and Reporting in Patients With Heart Failure: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07021599
- Acronym / sponsor ID
- AISEARHF / 2024.587
- Conditions
- Heart Failure
- Keywords
- Echocardiogram, Artificial Intelligence, Alogrithm, Echocardiological image analysis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 514 participants (estimated)
- Lead sponsor
- Prince of Wales Hospital, Shatin, Hong KongUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 3 Jul 2028 (estimated)
- Study completion
- 3 Dec 2028 (estimated)
- First posted
- 15 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a non-inferiority, three-year, multicenter, double-blinded randomized controlled study of an AI versus experienced sonographer echocardiogram analysis in HF patients. Consecutive patients presented for echocardiogram examination with new or worsening HF symptom and positive HF blood markers will be recruited. A target of 514 patients will be randomized 1:1 to receive either AI or sonographer echocardiogram analysis. The primary endpoint of diagnostic accuracy is the complete agreement of disease grading with an experienced cardiologist (American Society of Echocardiography level III) using a standardized grading chart. Important secondary endpoints include the time used for echocardiogram report drafting and report endorsement, 6-month heart failure symptom and hospitalization, and the cost-effectiveness of AI to increase echocardiogram service. Clinical, biochemical and echocardiographic predictors of worsening of heart failure and hospitalization will be identified.
Detailed description
Background Unmet Need for Streamlined Echocardiogram Algorithm Heart failure (HF) is a global pandemic affecting more than 64 million people in the world.
In Hong Kong, the prevalence of HF is estimated to be 2-3% with a steep rise of new onset HF hospitalization in the older age group. The estimated annual worldwide economic burden of HF was 108 billion United States dollars, with direct costs to healthcare systems accounted for 60% and indirect costs to society driven by premature mortality, morbidity and lost productivity accounted for the remaining 40%. Timely diagnosis of HF etiology with early appropriate treatment are critical to reduce HF hospitalization and mortality. While HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) requires different guideline directed medical therapy (GDMT), HF patients with severe valvular heart disease requires interventional treatment. Echocardiogram (cardiac ultrasound) is the key diagnosticmodality to phenotype HF and to guide subsequent appropriate treatment. Access to echocardiogram in Asia Pacific is severely limited (e.g. average waiting time in Hong Kong for routine echocardiogram is 12-18 months), which results in delay in appropriate treatment and hence poor outcomes. While image acquisition is easier to teach, analysis in echocardiogram is time consuming and requires years of training to become proficient, and yet has significant inter-observer variability. Therefore, there is a shortage of fully trained sonographers globally. A streamlined echocardiogram analysis pathway that can enhance the efficiency while improving the diagnostic accuracy of HF etiology is appealing.
Emerging role of Artificial Intelligence in Echocardiogram Artificial intelligence (AI) has emerged as a useful tool with the potential to enhance cardiovascular care including in disease diagnosis, treatment guidance and outcome prediction. Collaborator of this study, David Ouyang et al., has developed machine learning algorithm for fully automated assessment of left ventricular ejection function (LVEF), aortic valve stenosis (AS) and mitral valve regurgitation (MR), with similar accuracy compared to manual analysis by experienced sonographers with reference to cardiologists ("gold standard"). Similar works has also been done by other teams. However, most of these validation studies are conducted based on retrospective echocardiogram cohort. Besides, there can be bias when a different sonographer than the scanning sonographer interprets the images, and that potentially compromised the real-life diagnostic accuracy of sonographers.
Local Heart Failure Data and Application Artificial Intelligence in Echocardiogram Studies from our team has demonstrated that early diagnosis and intensified HF GDMT can reduce HF hospitalization from 13.1% to 8.6% (Hazard ratio = 0.65, p<0.01). Besides, a strong association of 30-day unplanned HF hospitalization with severe valvular heart disease, mostly AS or MR, was found (Odd ratio =72.04, p=0.03). This implies that early phenotyping the mechanism of HF is important. From our unpublished pilot data of patients presented with HF symptom, echocardiogram image acquisition took only 54.2% of the total echocardiogram process time while the remaining were used for analysis by sonographer. When compared, AI used a significantly shorter time for echocardiogram analysis (324 seconds vs 1057 seconds, p<0.01), with a 91.6% agreement rate on LVEF grading and severity of AS and MR. However, this pilot data was collected retrospectively, and the sample size was small. Therefore, it remains unclear whether AI is as accurate and more efficient than experienced sonographers in analyzing multiple possible echocardiogram abnormalities that can interact with each other for HF patients. Moreover, whether the addition of AI analysis will affect the final grading by cardiologists has not been studied.
In this research project proposal, Investigator aim to assess whether a tailored AI echocardiogram analysis and reporting system is as accurate as an experienced sonographer in HF patients by conducting a multicenter double-blinded randomized controlled study.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tailored AI echocardiogram analysis and reporting system | Experimental | Diagnostic Test: Tailored AI echocardiogram analysis and reporting systemAn experienced cardiologist will be provided with AI's measurements, draft disease grading and report for review. The experienced cardiologist will provide a final grading of left ventricular function, AS and MR on the standardized grading chart, and endorse the final echocardiogram report. |
| Echocardiologist interpretation and analysis of Echo images | Active comparator | Diagnostic Test: Tailored AI echocardiogram analysis and reporting systemAn experienced cardiologist (with American Society of Echocardiography level III capacity), will be provided with sonographer's measurements, draft disease grading and report for review. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Aged 18 years or above
- Has new or worsening of heart failure symptoms
- Elevated heart failure blood markers (N-terminal prohormone of brain natriuretic peptide, "NTproBNP") within 3 months from enrolment or by point-of-care blood test, to ensure that the patient's symptoms are cardiac origin
- Provision of written informed consent
Key exclusion criteria (4 listed)
- Known severe valvular heart disease
- Prior prosthetic valve implantation
- Previously known or suspected >=severe tricuspid regurgitation, >=moderate aortic regurgitation, >=moderate mitral stenosis or pericardial disease during detected during image acquisition
- Insufficient image quality for proper analysis determined by the scanning sonographer (estimated to be 15% of all echocardiograms screened)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tailored AI echocardiogram analysis and reporting systemIn the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized. | Diagnostic test | Echocardiologist interpretation and analysis of Echo images, Tailored AI echocardiogram analysis and reporting system |
Primary outcome
Rate of complete agreement in LVEF assessments
Time frame: 6 month
To assess the rate of agreement in LVEF assessments between AI and sonographers with final adjudication by experienced cardiologist
Rate of complete agreement in assessments of AS severity
Time frame: 6 month
To assess the rate of agreement in severity of AS assessments between AI and sonographers with final adjudication by experienced cardiologist
Rate of complete agreement in assessment of MR severity
Time frame: 6 month
To assess the rate of agreement in severity of MR assessments between AI and sonographers with final adjudication by experienced cardiologist
23 secondary outcomes
Time used for image acquisition echocardiogram process
Time frame: 6 month
Time used forreport drafting echocardiogram process
Time frame: 6 month
Time used for report endorsement
Time frame: 6 month
Time used for total echocardiogram process
Time frame: 6 month
NYHA classification
Time frame: 6 month
Symptom burden
Time frame: 6 month
NTproBNP level
Time frame: 6 month
Rate of heart failure hospitalisation
Time frame: 6 month
Rate of all-cause mortality
Time frame: 6 month
Dosage of GDMT
Time frame: 6 month
Rate of valvular intervention
Time frame: 6 month
Rate of LVEF assessment change made by cardiologist on AI generated reports
Time frame: 6 month
Rate of change in severity of AS made by cardiologist on AI generated reports
Time frame: 6 month
Rate of change in severity of MR made by cardiologist on AI generated reports
Time frame: 6 month
Subgroup analysis of LVEF agreement rate in low complexity disease
Time frame: 6 month
Subgroup analysis of LVEF agreement rate in intermediate complexity disease
Time frame: 6 month
Subgroup analysis of LVEF agreement rate in high complexity disease
Time frame: 6 month
Subgroup analysis of severity of AS agreement rate in low complexity disease
Time frame: 6 month
Subgroup analysis of severity of AS agreement rate in intermediate complexity disease
Time frame: 6 month
Subgroup analysis of severity of AS agreement rate in high complexity disease
Time frame: 6 month
Subgroup analysis of severity of MR agreement rate in low complexity disease
Time frame: 6 month
Subgroup analysis of severity of MR agreement rate in intermediate complexity disease
Time frame: 6 month
Subgroup analysis of severity of MR agreement rate in high complexity disease
Time frame: 6 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tailored AI echocardiogram analysis and reporting system in people with Heart Failure, run by Prince of Wales Hospital, Shatin, Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of complete agreement in LVEF assessments (time frame: 6 month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.